Common Blood Pressure Drug Shows Promise for Treating ADHD Symptoms

In a groundbreaking study, researchers have discovered that amlodipine, a widely used blood pressure medication, could offer a safer alternative for managing attention-deficit/treatment/drc-20350895″ title=”Attention-deficit/hyperactivity disorder (…) in children – Mayo Clinic”>hyperactivity disorder (ADHD) symptoms. This finding, backed by both animal and human genetic data, suggests a potential new pathway for treating ADHD, which affects approximately 9.4 percent of children and 4.4 percent of adults in the United States, according to the Centers for Disease Control and Prevention (CDC).

The study, published in Neuropsychopharmacology, involved testing five potential drugs in rats that exhibited ADHD-like symptoms. Among the drugs tested, only amlodipine significantly reduced hyperactivity. To further validate these findings, the team conducted tests on zebrafish, sharing about 70 percent of genes with humans. The results showed that amlodipine also reduced hyperactivity and impulsivity in these fish, which are core symptoms of ADHD. Further analysis of the fish revealed that amlodipine crosses the blood-brain barrier, directly influencing brain function. This was the first time such a discovery was made, underscoring the potential of amlodipine as a neuroactive substance.

Next, the researchers analyzed human genetic data and found a remarkable link between ADHD and the same calcium channels in the brain targeted by amlodipine. This suggests a potential brain pathway for future treatments. Additionally, an exploration of UK-wide patient data indicated that individuals taking amlodipine reported fewer mood swings and less risk-taking behavior, further supporting its potential as a new ADHD treatment.

“Repurposing amlodipine, a well-established blood pressure medication, offers a promising and swift pathway to address ADHD symptoms,” cited Dr. Matthew Parker, one of the lead researchers involved in the study. “Our research indicates that, due to its existing approval and safety profile, amlodipine could be rapidly redeployed as a treatment option for ADHD, potentially providing relief to patients sooner than developing new medications.”

Current ADHD Treatments and Their Limitations

Current ADHD medications, such as stimulants like Adderall and methylphenidate, and non-stimulants like Strattera, are effective but come with significant side effects, including appetite loss, high blood pressure, headaches, and sleep disturbances. Long-term use also carries a risk of misuse and abuse, making the search for new, safer treatments a critical priority.

The UK study findings suggest that amlodipine, which is already widely used and well-tolerated, could offer a safer treatment option for ADHD. This is particularly promising for the approximately 25 percent of patients who do not respond well to current medications, highlighting the urgent need for alternative treatments.

Practical Applications and Potential Benefits

For U.S. patients, the potential repurposing of amlodipine could mean quicker access to new treatment options. Currently, the development of new medications can take years, involving extensive clinical trials and costly research. By repurposing amlodipine, which is already approved by the Food and Drug Administration (FDA) and proven to be safe, the process could be significantly accelerated.

Further, amlodipine’s safety profile and widespread use mean it could be prescribed off-label to adult patients with ADHD, as investigations would show.

Implications for the U.S. Healthcare System and Beyond

If widely adopted, amlodipine’s repurposing could lead to significant cost savings for the healthcare system. Less reliance on pharmaceuticals with severe side effects could lessen the financial burden of healthcare costs prior to having to utilize treatments around, for example, managing increased blood pressure.
Additionally, repurposing existing medications often means counseling patients to avoid abuse, which could lead to lower healthcare expenses tied to misuse and abuse. By reducing the side effects of current ADHD medications, amlodipine could potentially improve patient quality of life and adherence to treatment.

However, it is important to note that further clinical trials and research are needed to fully understand the efficacy and long-term effects of amlodipine in treating ADHD. Although these findings are promising, they are still preliminary and should be approached with caution.

Expert Opinions on the Study

Rebecca Miles, a pediatric psychiatrist from Children’s National Medical Center, offered her thoughts on the study’s implications.

“The finding that amlodipine could potentially treat ADHD is particularly promising, as it offers a safer alternative to current medications with significant side effects,”.

“Given the widespread use and safety profile of amlodipine, it is exciting to think about potential for a rapid deployment of this treatment for ADHD patients who may not respond well to current therapies”.

— Rebecca Miles, pediatric psychiatrist, Children’s National Medical Center

Conclusion

The potential for amlodipine to treat ADHD symptoms marks a significant step forward in the search for safer, more effective treatments. As research continues, it is essential to maintain a balanced approach, acknowledging both the potential benefits and the need for further investigation. For the millions of Americans living with ADHD, this discovery offers a glimmer of hope for a treatment option that is both effective and safe.